Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

BACKGROUND: Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Flaherty, Keith T., Infante, Jeffery R., Daud, Adil, Gonzalez, Rene, Kefford, Richard F., Sosman, Jeffrey, Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Ibrahim, Nageatte, Kudchadkar, Ragini, Burris, Howard A., Falchook, Gerald, Algazi, Alain, Lewis, Karl, Long, Georgina V., Puzanov, Igor, Lebowitz, Peter, Singh, Ajay, Little, Shonda, Sun, Peng, Allred, Alicia, Ouellet, Daniele, Kim, Kevin B., Patel, Kiran, Weber, Jeffrey
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3549295/
https://ncbi.nlm.nih.gov/pubmed/23020132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1210093
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados